1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PDE 4 Inhibitors Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for PDE 4 Inhibitors by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for PDE 4 Inhibitors by Country/Region, 2018, 2022 & 2029
2.2 PDE 4 Inhibitors Segment by Type
2.2.1 Rolipram
2.2.2 Tetomilast
2.2.3 Cilomilast
2.2.4 Criborole
2.2.5 Apremilast
2.2.6 Roflumilast
2.2.7 Others
2.3 PDE 4 Inhibitors Sales by Type
2.3.1 Global PDE 4 Inhibitors Sales Market Share by Type (2018-2023)
2.3.2 Global PDE 4 Inhibitors Revenue and Market Share by Type (2018-2023)
2.3.3 Global PDE 4 Inhibitors Sale Price by Type (2018-2023)
2.4 PDE 4 Inhibitors Segment by Application
2.4.1 Psoriasis
2.4.2 Chronic Obstructive Pulmonary Disease (COPD)
2.4.3 Asthma
2.4.4 Ankylosing Spondylitis (AS)
2.4.5 Inflammatory Bowel Disease (IBD)
2.4.6 Atopic Dermatitis
2.4.7 Rheumatoid Arthritis (RA)
2.4.8 Systemic Lupus Erythematosus (SLE)
2.4.9 Others
2.5 PDE 4 Inhibitors Sales by Application
2.5.1 Global PDE 4 Inhibitors Sale Market Share by Application (2018-2023)
2.5.2 Global PDE 4 Inhibitors Revenue and Market Share by Application (2018-2023)
2.5.3 Global PDE 4 Inhibitors Sale Price by Application (2018-2023)
3 Global PDE 4 Inhibitors by Company
3.1 Global PDE 4 Inhibitors Breakdown Data by Company
3.1.1 Global PDE 4 Inhibitors Annual Sales by Company (2018-2023)
3.1.2 Global PDE 4 Inhibitors Sales Market Share by Company (2018-2023)
3.2 Global PDE 4 Inhibitors Annual Revenue by Company (2018-2023)
3.2.1 Global PDE 4 Inhibitors Revenue by Company (2018-2023)
3.2.2 Global PDE 4 Inhibitors Revenue Market Share by Company (2018-2023)
3.3 Global PDE 4 Inhibitors Sale Price by Company
3.4 Key Manufacturers PDE 4 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PDE 4 Inhibitors Product Location Distribution
3.4.2 Players PDE 4 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for PDE 4 Inhibitors by Geographic Region
4.1 World Historic PDE 4 Inhibitors Market Size by Geographic Region (2018-2023)
4.1.1 Global PDE 4 Inhibitors Annual Sales by Geographic Region (2018-2023)
4.1.2 Global PDE 4 Inhibitors Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic PDE 4 Inhibitors Market Size by Country/Region (2018-2023)
4.2.1 Global PDE 4 Inhibitors Annual Sales by Country/Region (2018-2023)
4.2.2 Global PDE 4 Inhibitors Annual Revenue by Country/Region (2018-2023)
4.3 Americas PDE 4 Inhibitors Sales Growth
4.4 APAC PDE 4 Inhibitors Sales Growth
4.5 Europe PDE 4 Inhibitors Sales Growth
4.6 Middle East & Africa PDE 4 Inhibitors Sales Growth
5 Americas
5.1 Americas PDE 4 Inhibitors Sales by Country
5.1.1 Americas PDE 4 Inhibitors Sales by Country (2018-2023)
5.1.2 Americas PDE 4 Inhibitors Revenue by Country (2018-2023)
5.2 Americas PDE 4 Inhibitors Sales by Type
5.3 Americas PDE 4 Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PDE 4 Inhibitors Sales by Region
6.1.1 APAC PDE 4 Inhibitors Sales by Region (2018-2023)
6.1.2 APAC PDE 4 Inhibitors Revenue by Region (2018-2023)
6.2 APAC PDE 4 Inhibitors Sales by Type
6.3 APAC PDE 4 Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe PDE 4 Inhibitors by Country
7.1.1 Europe PDE 4 Inhibitors Sales by Country (2018-2023)
7.1.2 Europe PDE 4 Inhibitors Revenue by Country (2018-2023)
7.2 Europe PDE 4 Inhibitors Sales by Type
7.3 Europe PDE 4 Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PDE 4 Inhibitors by Country
8.1.1 Middle East & Africa PDE 4 Inhibitors Sales by Country (2018-2023)
8.1.2 Middle East & Africa PDE 4 Inhibitors Revenue by Country (2018-2023)
8.2 Middle East & Africa PDE 4 Inhibitors Sales by Type
8.3 Middle East & Africa PDE 4 Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PDE 4 Inhibitors
10.3 Manufacturing Process Analysis of PDE 4 Inhibitors
10.4 Industry Chain Structure of PDE 4 Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PDE 4 Inhibitors Distributors
11.3 PDE 4 Inhibitors Customer
12 World Forecast Review for PDE 4 Inhibitors by Geographic Region
12.1 Global PDE 4 Inhibitors Market Size Forecast by Region
12.1.1 Global PDE 4 Inhibitors Forecast by Region (2024-2029)
12.1.2 Global PDE 4 Inhibitors Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PDE 4 Inhibitors Forecast by Type
12.7 Global PDE 4 Inhibitors Forecast by Application
13 Key Players Analysis
13.1 Pfizer(Anacor)
13.1.1 Pfizer(Anacor) Company Information
13.1.2 Pfizer(Anacor) PDE 4 Inhibitors Product Portfolios and Specifications
13.1.3 Pfizer(Anacor) PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer(Anacor) Main Business Overview
13.1.5 Pfizer(Anacor) Latest Developments
13.2 Arcutis Biotherapeutics
13.2.1 Arcutis Biotherapeutics Company Information
13.2.2 Arcutis Biotherapeutics PDE 4 Inhibitors Product Portfolios and Specifications
13.2.3 Arcutis Biotherapeutics PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Arcutis Biotherapeutics Main Business Overview
13.2.5 Arcutis Biotherapeutics Latest Developments
13.3 UNION Therapeutics
13.3.1 UNION Therapeutics Company Information
13.3.2 UNION Therapeutics PDE 4 Inhibitors Product Portfolios and Specifications
13.3.3 UNION Therapeutics PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 UNION Therapeutics Main Business Overview
13.3.5 UNION Therapeutics Latest Developments
13.4 Innovent Biologics, Inc.
13.4.1 Innovent Biologics, Inc. Company Information
13.4.2 Innovent Biologics, Inc. PDE 4 Inhibitors Product Portfolios and Specifications
13.4.3 Innovent Biologics, Inc. PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Innovent Biologics, Inc. Main Business Overview
13.4.5 Innovent Biologics, Inc. Latest Developments
13.5 Amgen
13.5.1 Amgen Company Information
13.5.2 Amgen PDE 4 Inhibitors Product Portfolios and Specifications
13.5.3 Amgen PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Amgen Main Business Overview
13.5.5 Amgen Latest Developments
13.6 Ralington pharma LLP
13.6.1 Ralington pharma LLP Company Information
13.6.2 Ralington pharma LLP PDE 4 Inhibitors Product Portfolios and Specifications
13.6.3 Ralington pharma LLP PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Ralington pharma LLP Main Business Overview
13.6.5 Ralington pharma LLP Latest Developments
13.7 Beijing Biolab Technology Co., Ltd.
13.7.1 Beijing Biolab Technology Co., Ltd. Company Information
13.7.2 Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Product Portfolios and Specifications
13.7.3 Beijing Biolab Technology Co., Ltd. PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Beijing Biolab Technology Co., Ltd. Main Business Overview
13.7.5 Beijing Biolab Technology Co., Ltd. Latest Developments
13.8 Nycomed
13.8.1 Nycomed Company Information
13.8.2 Nycomed PDE 4 Inhibitors Product Portfolios and Specifications
13.8.3 Nycomed PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Nycomed Main Business Overview
13.8.5 Nycomed Latest Developments
13.9 Forest
13.9.1 Forest Company Information
13.9.2 Forest PDE 4 Inhibitors Product Portfolios and Specifications
13.9.3 Forest PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Forest Main Business Overview
13.9.5 Forest Latest Developments
13.10 Bristol Myers
13.10.1 Bristol Myers Company Information
13.10.2 Bristol Myers PDE 4 Inhibitors Product Portfolios and Specifications
13.10.3 Bristol Myers PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Bristol Myers Main Business Overview
13.10.5 Bristol Myers Latest Developments
13.11 GSK
13.11.1 GSK Company Information
13.11.2 GSK PDE 4 Inhibitors Product Portfolios and Specifications
13.11.3 GSK PDE 4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 GSK Main Business Overview
13.11.5 GSK Latest Developments
14 Research Findings and Conclusion
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer